The recent study underscores the limited eligibility for new monoclonal antibody treatments in early Alzheimer’s patients, emphasizing the need for more inclusive research. Explore the detailed findings to understand the implications for treatment availability in diverse populations.

Columbia researchers have identified the specific brain injuries that may underlie hidden consciousness in brain injury patients. This discovery could enable physicians to more quickly identify affected patients and better predict recovery, moving the detection of cognitive motor dissociation one step closer to general clinical use.

The FDA’s recent approval of Akeega, a combination therapy for BRCA-mutated mCRPC, marks a significant advancement in targeted treatment. This approval, based on the MAGNITUDE study, offers a new therapeutic option for patients, supported by robust clinical data.

Explore the complexities of treating small cell lung cancer (SCLC) after platinum-based therapy failure, including insights into immune checkpoint inhibitors, the preference for lurbinectedin, and the potential of liquid biopsies. Join Dr. Misty Shields in understanding the challenges and opportunities in this evolving field.

The recent study on MCL reveals a promising approach in identifying high-risk patients through the combination of MIPI-c and p53 overexpression. This method may guide the development of targeted therapies and personalized treatment plans, addressing the unmet needs of those at the highest risk.

This multinational study offers a comprehensive analysis of the association between protracted low dose exposure to ionising radiation and solid cancer mortality. Physicians and healthcare professionals may find the results significant in understanding and enhancing radiation protection, especially in contemporary medical settings.